| February 5, 2011 – Saturday - All Faculty are Confirmed |
| 6:30AM - 7:20AM |
Breakfast |
| 6:30AM |
Registration |
| 7:20AM |
Welcome, Introductions and CME Pre Test |
Drs. Lisa Carey and Dennis Slamon |
 |
SESSION 1: ER-POSITIVE DISEASE: Testing and Therapy – CHAIR: Hy Muss |
|
| 7:30AM |
Case Study -Testing for ER-Positive Disease: The New Landscape Due to “Game-Changing Guidelines”: Practical Implications in the Clinic Today for Aiding Treatment Decision Making |
Andrea Richardson |
| 8:00AM |
Case-Study - Treatment of Adjuvant and Neoadjuvant ER-Positive Disease |
Hy Muss |
| 8:20AM |
Case Study - Treatment of Advanced/Metastatic ER-Positive Disease |
Paul Goss |
| 8:40AM |
Point-CounterPoint Debate:
Mammaprint versus OncotypeDX versus IHC Testing: Which of these three tests is most useful? In which patients should each be used? Who? Why? |
Use 70-Gene Micro-Array Assay: Lajos Pusztai; Use 21-Gene Panel Assey: Craig Allred
Use IHC Test: Hy Muss |
| 9:10AM |
Session 1 Additional Case Studies – The learners select treatment options using the ARS handsets. |
Lajos Pusztai |
| 9:30AM |
Session 1 Roundtable Panel Discussion:
Describe for which ER-positive patients each of these three tests should be used and in what clinical situations. Discuss the remaining issues and controversies. |
Session 1 Faculty |
| 9:45AM |
Q & A |
Learners and Faculty |
| 10:00AM |
BREAK |
EXHIBITS |
|
Session 2: HER-2 DISEASE: Testing and Therapy – CHAIR: Dennis Slamon |
|
| 10:15AM |
Case Study -
Treatment of Early-Stage Patients with HER2-Positive Disease |
Edith Perez |
| 10:35AM |
Case Study - Treatment of Advanced/Metastatic HER2-Positive Disease |
Mark Pegram |
| 10:55AM |
Session 2 Additional Case Studies – The learners select treatment options using the ARS handsets. |
Harold Burstein |
| 11:10AM |
Session 2 Roundtable Panel Discussion: Describe for which HER2-positive regimens should be used and in what clinical situations. Discuss the remaining issues and controversies. |
Session 2 Faculty |
| 11:20AM |
Q & A |
Learners and Faculty |
| 11:30AM |
Lunch with the Professors, and, Exhibits |
|
|
Session 3: TREATING TRIPLE-NEGATIVE DISEASE – CHAIR: Lisa Carey |
|
| 12:30PM |
Case Study -Treatment of Adjuvant and Neoadjuvant Disease in Patients with Triple-Negative Breast Cancer |
Lisa Carey |
| 12:50PM |
Case Study - Treatment of Patients with Advanced or Metastatic Triple-Negative Breast Cancer: How does PARP inhibition affect the current treatment paradigm for advanced or metastatic breast cancer patients? |
Joyce O'Shaughnessy |
| 1:10PM |
Session 3 Additional Case Studies – The learners select treatment options using the ARS handsets. |
Judy Garber |
| 1:30PM |
Session 3 Roundtable Panel Discussion: Describe which drug regimens should be used and in what clinical situations for triple-negative breast cancer patients. Discuss the remaining issues and controversies. |
Session 3 Faculty |
| 1:50PM |
Q & A |
Learners and Faculty |
2:10PM
|
BREAK |
|
|
| Session 4: SYSTEMIC AND LOCAL-REGIONAL THERAPIES AND OTHER PATIENT MANAGEMENT STRATEGIES FOR ALL SUBTYPES OF BREAST CANCER – CHAIR: Mark Pegram |
|
| 2:30PM |
Case Study - The new dilemma: targeting VEGF and/or the VEGFR receptor axis? What is the precise role of bevacizumab and multi-kinase inhibitors? |
Maura Dickler |
| 2:50PM |
Case Study - Microtubule Inhibition: A new treatment paradigm for advanced or metastatic breast cancer patients? |
Hope Rugo |
| 3:10PM |
Case Study - Personalizing Local-Regional Breast Cancer Therapies – How Have We Advanced Our Strategies to Improve Outcomes in the Clinic Today? |
Armando Giuliiano |
| 3:30PM |
Case Study - Therapeutic strategies directed at prevention and management of bone metastases in breast cancer patients. Does this represent another dilemma or a new opportunity in the clinic today? |
Allan Lipton |
| 3:50PM |
Case Study - Brain Metastases – What are the newest and optimal clinical strategies for patients with breast cancer? |
Carey Anders |
| 4:05PM |
Session 4 Additional Case Studies – The learners select treatment options using the ARS handsets. |
Allan Lipton |
| 4:20PM |
Session 4 Final Roundtable Panel Discussion |
Session 4 Faculty |
| 4:40PM |
Final Q & A |
Learners and Faculty |
| 4:55PM |
CME post test and comparisons of pre-test and post-test answers |
Dennis Slamon |
| 5:00PM |
ADJOURN |
|
